1. Home
  2. AX vs AKRO Comparison

AX vs AKRO Comparison

Compare AX & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axos Financial Inc.

AX

Axos Financial Inc.

HOLD

Current Price

$85.71

Market Cap

4.8B

Sector

Finance

ML Signal

HOLD

Logo Akero Therapeutics Inc.

AKRO

Akero Therapeutics Inc.

HOLD

Current Price

$54.65

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AX
AKRO
Founded
1999
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.5B
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
AX
AKRO
Price
$85.71
$54.65
Analyst Decision
Strong Buy
Buy
Analyst Count
7
11
Target Price
$97.07
$73.56
AVG Volume (30 Days)
284.9K
2.4M
Earning Date
01-27-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
7.44
N/A
Revenue
$1,202,571,000.00
N/A
Revenue This Year
$16.70
N/A
Revenue Next Year
$9.76
N/A
P/E Ratio
$11.48
N/A
Revenue Growth
6.69
N/A
52 Week Low
$54.46
$21.34
52 Week High
$93.84
$58.40

Technical Indicators

Market Signals
Indicator
AX
AKRO
Relative Strength Index (RSI) 61.46 68.63
Support Level $84.52 $54.30
Resistance Level $86.87 $54.70
Average True Range (ATR) 2.26 0.17
MACD 0.43 -0.10
Stochastic Oscillator 80.39 71.07

Price Performance

Historical Comparison
AX
AKRO

About AX Axos Financial Inc.

Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: